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Host responseAbstract Periodontal diseases with their poly microbial etiology, are a major cause of tooth mor-
tality in the adult population. Current treatment modalities have resulted only in arresting the dis-
ease progression but have not cured the disease completely, nor do they prevent the recurrence.
Hence there is a need for more sophisticated therapeutic modalities which may include vaccines tar-
geting putative periodontal pathogens. No periodontal vaccine trials have been successful in satis-
fying all requirements of an ideal periodontal vaccine. Periodontal vaccines could emerge as an
adjunct to mechanical therapy in future.
ª 2014 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Contents
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In the current paradigm of periodontal disease, the periodontal
pathogens are essential for disease initiation, however, the
extent and severity of tissue destruction largely depend on
the nature of the host microbial interactions. Periodontal dis-
eases are immune inﬂammatory responses induced by microor-
ganisms in dental plaque which, harbored within a susceptible
periodontium contributes to tissue destruction, bone loss and
eventually tooth loss.
Speciﬁc molecules have been recognized that signal peri-
odontal tissue destruction as the inﬂammatory response
develops. They can be broadly divided into (a) microbial
virulence factors (b) those derived from host immune
inﬂammatory response. Bacteria are important because they
drive and perpetuate the inﬂammation but the great major-
ity of tissue breakdown results from host inﬂammatory
processes. Microbial virulence factors include (a) lipopoly-
saccharides (b) bacterial enzymes and noxious products (c)
microbial invasion strategies (d) ﬁmbriae (e) bacterial
deoxyribonucleic acid and extracellular deoxyribonucleic
acid. The host derived inﬂammatory mediators can be
divided as (a) cytokines (b) prostaglandins and (c) matrix
metalloproteinases.
Till date, no preventive modality exists for periodontal dis-
ease and treatment rendered is palliative. The availability of
periodontal vaccine would not only prevent or modulate the
course of periodontal diseases, but also enhance the quality
of life of people for whom periodontal treatment cannot be
obtained easily.2. Bacterial etiology
Acceptance of the speciﬁc plaque hypothesis was spurred by
the recognition of Actinobacillus actinomycetemcomitans as
a pathogen in localized aggressive periodontitis1.
Porphyromonas gingivalis, A. actinomycetemcomitans, Trep-
onema denticola, Tannerella forsythia were implicated as the
key pathogens in the etiology of periodontal disease. Accord-
ing to Loesche WJ in 1976, the speciﬁc plaque hypothesis
states that only certain plaque is pathogenic, and its pathoge-
nicity depends on the presence or increase in the speciﬁc
microorganisms2.
With the rapid growth of microbial genome sequencing and
bioinformatics analysis tools, we have the potential to examine
all the genes and proteins from any human pathogen3. This
technique has the capability to provide us with new targets
for anti-microbial drugs and vaccines. However, to realize this,
potential new bioinformatics and experimental approaches for
the selection of these targets from the myriad of available
candidates are required.3. Host response in periodontal disease
The host defense against periodontopathogenic bacteria com-
prises innate and acquired immunity. Saliva, GCF and the
keratinocytes are some of the key agents that play a key role
in innate immune response4,5. Neutrophils are the primary leu-
kocytes to act in innate immune response. Macrophages and
dendritic cells are also important innate immune cells which
express pattern recognition receptors (PRRs) that interact with
the speciﬁc molecular structures on microorganisms called
microbe associated molecular patterns (MAMPs) to signal
immune responses6,7. However innate immune response is
nonspeciﬁc hence results in excessive host tissue damage with-
out effective antigenic clearance8,9. Adaptive immunity has
evolved to provide a focused and intense defense against
infections that overwhelm innate immune responses in the
tissues10–12. Adaptive immunity is slower and reliant on
complex interactions between antigen-presenting cells and T
and B lymphocytes, cytotoxic T cells and antibodies13–15.
The increase in antibody titer or antigen speciﬁc T–cells result-
ing from an exposure of a host to an antigen for the ﬁrst time is
referred to as the primary response. The secondary response
develops after a subsequent exposure to that same antigen.
Because of the generation of memory, the secondary response
 Is more rapid in onset
 Is longer in duration
 Is greater in strength due to higher titers
 For B cells may have greater speciﬁcity, against the antigen
compared with the primary response.
The expanded pool of memory cells provides a reservoir of
cells that is sustained for years by constant stimulation of anti-
gen maintained by follicular DCs (Dentritic Cells). The pri-
mary response takes slightly more than one week to become
measurable and biologically or clinically useful. Secondary
responses are clinically measurable within 1 to 3 days and
are so effective that an individual may not be aware of the
infection. The immune response to pathogenic microorganisms
involves the integration at the molecular, cellular, and organ
level of elements often categorized as being part of the innate
immune system or the adaptive immune system. Periodonto-
pathogens have however developed mechanisms to inhibit
and evade cell-mediated and humoral immune responses16–18.4. Vaccine
Vaccine is the name applied generally to a dead or attenuated
living infectious material introduced into the body with the
object of increasing resistance or eliminating the disease.
Vaccination is the development of immunity, or resistance to
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sider the individual immune to a subsequent infection. The
foremost step in vaccine development is identiﬁcation of an
antigenic component from various organisms that can provide
immune protection. Antigens of infectious pathogenic bacteria
and viruses have been targets for a variety of vaccines against a
number of infectious diseases. The antigens of a vaccine induce
clonal expansion in speciﬁc T or B cells leaving behind a pop-
ulation of memory cells.
Vaccines may be synthetic or natural monovalent or poly-
valent. Here the organism is isolated or created and is unable
to cause full blown disease. But still retains antigenic compo-
nents which induce host immune response. Vaccines may be
prepared by
(a) killing the organism using formalin-called inactivated or
killed vaccine.
(b) using only antigenic part of the disease causing organ-
ism, for example the capsule, the ﬂagella, the part of
the protein cell wall-acellular vaccines19.
(c) vaccines may be prepared by weakening a live microor-
ganism by aging it or altering growth condition-attenu-
ated vaccines19.
(d) toxoids are vaccines from toxins, which are adsorbed
onto aluminum salts to decrease their harmful effects
and is administered with an ‘‘adjuvant’’ which can have
effects on antigen delivery, immune modulatory cyto-
kines, and antigen – presenting cells20.
Characteristics of an effective vaccine include safety, pro-
tectivity, the ability to provide sustained protection, stimula-
tion of protective T-cells and the ability to produce
neutralizing antibodies. Practical considerations like cost-
effectiveness, biological stability, access and minimum contra-
indications and side effects are also important21.5. Periodontal vaccine
In the early twentieth century, three periodontal vaccines were
employed which include pure cultures of streptococcus and
other organisms, autogenous vaccines, stock vaccines. Exam-
ples include Vancott’s vaccine and Inava endocarp vaccine22.
The search for the etiologic agents of periodontal disease
and the vaccines ended inconclusively; probably the most
important reason for the failure was the inability to conduct
adequately controlled clinical trials and experiments. Most
experiments on immunization of periodontitis, despite itsTable 1 Summary of ﬁndings from animal study models for active
Bacteria Virulence factor
P. gingivalis Whole-cell
Fimbriae
Gingipains(RgpA and Rgp B)
Gingipain R
Gene vaccine
Whole-cell +Rgp
E. coli cloned with P. gingivalis se
A. actinomycetemcomitans Leucotoxin
F. nucleatum and P. gingivalis in combinationpoly–infectious nature, have been directed toward a very lim-
ited number of antigenic components of a single speciﬁc path-
ogen; either P. gingivalis or A. actinomycetemcomitans. P.
gingivalis is the most potential vaccine candidate because this
pathogen carries several high-potent antigens, a lipopolysac-
charide (LPS) capsule, lipids, and outer membrane proteins
(OMP) which are used as subunits for development of active
immunization23.
5.1. Types of periodontal vaccination
5.1.1. Active immunization
Here, an individual immune system is stimulated by adminis-
trating killed or live attenuated products derived from micro-
organisms24 (Table 1). It is further classiﬁed as
 Whole bacterial cells eg: P. gingivalis whole cells. Serum
antibodies to whole cells and partially puriﬁed ﬁmbriae
from P. gingivalis were elevated in rats immunized with P.
gingivalis cells. Further activities of collagenase and cysteine
proteinases in periodontal tissue losses were decreased25. It
has also been reported that formalin killed whole cells of P.
gingivalis vaccine have resulted in blockage of PGE2
response to LPS challenge26.
 Sub unit vaccines e.g. using virulence factors of P. gingivalis
such as gingipains. P. gingivalis produces two classes of cys-
teine proteases that have been implicated in periodontal
pathogenesis. These are known as gingipains and include
lysine speciﬁc gingipain Kgp and the arginine speciﬁc gingi-
pains RgpA and RgpB. The gingipains can modulate the
immune system and disrupt immune inﬂammatory
responses potentially leading to increased tissue break-
down27. It has been reported that immunization with gingi-
pains prevents colonization with P. gingivalis and reduces
bone loss.28
 Synthetic peptides eg: ﬁmbrial peptide in the gnotobiotic rat
model. Synthetic peptides based on the protein structure of
ﬁmbrillin inhibit the adhesion of P. gingivalis to saliva
coated-hydroxyapatite crystals in vitro and their binding
domains are located at the carboxyl terminal region29
(Fig. 1).
5.1.2. Passive immunization
This approach employs preformed antibodies administered to
‘‘at risk’’ individuals or to individuals during ‘‘at risk’’ inter-
vals to interfere with microbial pathogenic processes. Hereimmunization vaccine trials in periodontitis30.
Author
Persson et al. (1994)
Evans et al. (1992)
Moritz et al. (1998)
Genco et al. (1998)
Ross et al. (2004)
Gibson III et al. (2001), Rajapakse et al. (2002)
quence DeCarlo et al. (2003)
Ebersole et al. (1990)
Gemmell et al. (2004)
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(Table 2). These antibodies were inoculated into host to bring
about passive immunization. Passive immunization has shown
to temporarily reduce P. gingivalis colonization and prevent
recolonization. Passive immunization can be done by murine
monoclonal antibodies: here antibodies are obtained by inocu-
lating antigens into mice and plantibodies––involves molecular
biologic techniques to express bacterial or viral antigens in
plants which could be used as orally administered vaccines.
(Fig. 1)5.1.3. Genetic immunization
Here, DNA plasmid encoding genes required for antigen pro-
duction are transferred to an individual. It can be divided as:
 Plasmid vaccines: plasmids are fused with the DNA of a
particular pathogen and inoculated in animal for antibody
production, however it may cause oncogenesis.
 Live viral vector vaccines: Variety of infectious but non dis-
ease causing DNA or RNA viruses or bacteria are engi-
neered to express the proteins of disease-producing
organism. Those vectors enter the body cells, produce pro-
teins and induce humoral or cellular immune response
(Fig. 1)Fig. 1 Pictorial representation of active immunizati6. Discussion
The major challenges in periodontal vaccine development are
that multiplicity of pathogenic microorganism indicates that
vaccine design against periodontitis could be very complex.
Bacterial whole cell or crude extract preparation for vacci-
nation is not desirable because the antigenic determinants of
bacteria potentially possess a high risk of cross-reactivity with
human counterparts. Further vaccines may be contaminated
with unwanted proteins or toxins, or even live viruses causing
a threat especially to hypersensitive individuals.
Supposedly killed vaccines may not have been properly
killed; attenuated vaccines may revert to the wild type30. This
could be of serious concern in an immunocompromised recipi-
ent. Animal models for vaccine trials may pose inconsistencies
with human models in major histocompatibility complex –
restriction of antigens presented by antigen presenting cells,
thus obscuring immunomodulant epitopes.
7. Future advances
(1) A genetically engineered obese diabetic mouse is a valu-
able tool for the study of periodontal disease and puta-
tive periodontal vaccines19.on, passive immunization and DNA vaccination.
Table 2 Summary of ﬁndings from human studies on passive
immunization in subjects with aggressive periodontitis or
chronic periodontitis30.
Bacterial antigen Author and study type
P. gingivalis
A. viscosus
P. intermedia
T. vincentii
T. denticola
Aukhil et al. (1988)
P. gingivalis
A. viscosus
A. actinomycetemcomitans (serotype a)
P. intermedia
Kohyama (1989)
P. gingivalis Chen et al. (1995)
P. gingivalis Johnson et al. (1993)
A. actinomycetemcomitans Sjo¨stro¨m et al. (1994)
P. gingivalis Mooney et al. (1995)
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as antigenic molecules in an attempt to stimulate anti-
gen–speciﬁc regulatory T-cells, secreting IL-10 and
Transforming growth factor b, may provide new clues
for periodontal disease prevention, through the induc-
tion of either immune tolerance or in effector function31.
(3) Strategies to enhance immunogenicity of antigenic com-
ponents of B or T lymphocytes such as immunization of
dentritic cells pulsed with antigens, use of improved
adjuvant formulas, use of plantibodies and the use of
transgenic microorganisms as antigen vectors.
8. Conclusion
However, the elimination of the periodontopathogens does not
eliminate the periodontal disease as proposed in the ecological
plaque hypothesis. It states that any change to the environ-
ment induces a response in the micro ﬂora, and vice versa.
Implicit in this hypothesis is that, although disease can be trea-
ted by targeting the putative pathogens directly,32 long-term
prevention will only be achieved by interfering with the under-
lying changes in the environment that drive the deleterious
shifts in the micro ﬂora. However vaccines targeting the
polymicrobial etiology of periodontal disease could act as an
important adjunct to mechanical debridement. Hence the con-
cept of periodontal vaccination is not a myth but a reality
which will come true in the near future if research is carried
out in the right manner in the right direction.
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